Filed USDMF for Sirolimus. Concord now DMFs for 9 products
Oct 2010
Successful participation in CPHI, Paris with its first independent booth.
Sept 2010
Successful launch of Tacrolimus in US market with its ANDA partner. Concord now supplies four products commercially in the US market.
Sept 2010
Foundation stone laid for state-of-the- art R&D facility. Another plant for low volume & high value products commissioned making the total number of manufacturing blocks as 16.
Aug 2010
Yet another expansion in the fermentation capacity by 25%. Total fermentation capacity now over 450 m3
30% increase in the total fermentation capacity by addition of another fermentation block.
June 2009
With the addition of two new products, Cyclosporine & Sirolimus, Concord is one of the few companies in the world supplying the entire immunosuppressant range of products.
May 2009
Concord is one of the front runners in the US market for Mycophenolate Mofetil with its first successful day 1 launch with its ANDA partners.
May 2009
Concord receives GMP certification by Australian TGA (Therapeutic Goods Administration) for couple of its products.
Jan 2009
Filed USDMF for Vancomycin HCl
Oct 2008
Accreditation certificate of Foreign Drug Manufacturer (AFM) received from Japanese Authorities.
Aug 2008
Filed US DMF for Mycophenolate Sodium
March 2008
Concord facility inspected by USFDA without any 483’s and the facility classified as acceptable.
